摘要
目的探讨T3、T4期直肠癌患者新辅助化疗效果及相关影响因素,为直肠癌患者选择更优治疗方案提供依据。方法选取91例接受新辅助化疗的局部进展期直肠癌患者作为研究对象,所有患者均采用XELOX化疗方案,化疗后根据实体肿瘤疗效评价标准,将患者分为完全缓解(CR)、部分缓解(PR)、病情稳定(SD)三组,并收集患者一般情况及化疗前后相关指标,观察肿瘤相关各指标的变化情况,同时运用单因素和多因素有序logistic回归方法分析影响新辅助化疗效果的相关因素。结果 91例患者中,CR完全缓解18例(19.78%),PR部分缓解40例(43.96%),SD疾病稳定33例(36.36%);多因素logistic回归分析显示:在调整了性别后,治疗前淋巴结转移情况是新辅助化疗疗效的独立影响因素(OR=1.731,95%CI:1.152～2.601)。结论局部晚期直肠癌患者能从新辅助治疗中获益,化疗前应对患者的性别、肿瘤直径大小和淋巴结转移情况进行了解,明确肿瘤生物学特性,最大限度地提高新辅助化疗疗效。
Objective To investigate the efficacy of neoadjuvant chemotherapy in patients with stage T3 and T4 rectal cancer and its related influencing factors, and to provide reference for the Locally advanced rectal cancer to choose optimal treatment schemes. Methods Ninety-one patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy from a hospital were selected, and after receiving XELOX chemotherapy, the patients were divided into three groups: complete remission (CR), partial remission (PR) and stable disease (SD), according to Response Evaluation Criteria in Solid Tumors.The general characteristics of patients and relevant clinical indicators before and after chemotherapy were collected to observe the changes of the indicators related to the cancer, and univariate and multivariate analysis were used to analyze the related factors affecting the efficacy of neoadjuvant chemotherapy. Results Of the 91 patients, 18 (19.78%) had complete remission, and 40 (43.96%) with partial remission, 33(36.36%) with stable disease. Multivariate analysis showed that lymph node metastasis before treatment was an independent factor affecting the efficacy of neoadjuvant chemotherapy after adjusting gender ( OR=1.731,95%CI : 1.152~2.601). Conclusion Patients with locally advanced rectal cancer can benefit from neoadjuvant therapy, to maximize the efficacy of neoadjuvant chemotherapy, the condition of patients including gender, tumor diameter, and the situation of lymph node metastasis should be considered before chemotherapy.
作者
叶倩
张秋菊
丛雨欣
李称
刘美娜
Ye Qian;Zhang Qiuju;Cong Yuxin;Li Cheng;Liu Meina(Department of Medical Statistics, Harbin Medical University, Harbin 150081, China)
出处
《中国医院统计》
2019年第2期81-84,共4页
Chinese Journal of Hospital Statistics
基金
国家自然科学基金(81502889)
黑龙江省教育厅项目(12531374)
关键词
直肠癌
新辅助化疗
病理完全缓解
影响因素
rectal cancer
neoadjuvant chemotherapy
pathological complete remission
influencing factor
